Elite Journal of Nursing and Health Sciences. Volume 2 Issue 6(2024), Pp. 50-68
https://epjournals.com/journals/EJNHS

Malaria During Pregnancy: Effects on Maternal Morbidity and Mortality

*Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda.
[2]School of Nursing Science, Kampala International University, Ishaka, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Malaria during pregnancy remains a major public health concern, particularly in sub-Saharan Africa, where the disease is endemic. Pregnant women are highly susceptible to malaria due to immunological changes and the presence of the placenta, which provides an ideal environment for Plasmodium falciparum sequestration. This condition, known as placental malaria, can lead to severe maternal anemia, pre-eclampsia, and increased risk of severe complications such as cerebral malaria and multi-organ failure, contributing significantly to maternal morbidity and mortality. The adverse effects of malaria in pregnancy extend beyond the mother to affect pregnancy outcomes, including increased risks of preterm birth, low birth weight, and stillbirth. Placental malaria disrupts nutrient and oxygen flow to the fetus, resulting in intrauterine growth restriction (IUGR) and higher rates of neonatal mortality. These outcomes underscore the critical need for effective preventive measures and prompt treatment strategies to protect both maternal and fetal health in malaria-endemic regions. Preventive strategies such as intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp) and the use of insecticide-treated nets (ITNs) have proven effective in reducing malaria incidence among pregnant women. Early diagnosis and appropriate treatment with artemisinin-based combination therapies (ACTs) are crucial for managing infections and preventing severe complications. Ongoing efforts to enhance these preventive and treatment measures are essential for reducing the burden of malaria during pregnancy and improving maternal and neonatal health outcomes.

Keywords: *Malaria**,** Pregnancy**,** Maternal morbidity**,** Maternal mortality**,** Plasmodium falciparum**,** Anemia*

Introduction

Malaria remains one of the most significant global health challenges, particularly affecting tropical and subtropical regions. It is caused by Plasmodium parasites, with Plasmodium falciparum being

the deadliest species. Malaria transmission occurs through the bite of infected Anopheles mosquitoes, with the highest burden observed in sub-Saharan Africa. In 2020, the World Health Organization (WHO) reported an estimated 241 million malaria cases and 627,000 deaths worldwide, highlighting the urgent need for effective control and prevention measures.[1-2] Among the populations at risk, pregnant women are particularly vulnerable to malaria infections due to physiological and immunological changes that occur during pregnancy. These changes can increase susceptibility to malaria, reduce the efficacy of the immune response, and exacerbate the severity of the disease. As a result, malaria during pregnancy poses significant risks to both maternal and fetal health, contributing to high rates of morbidity and mortality in endemic regions.[3-4] Maternal morbidity associated with malaria includes a range of complications such as severe anemia, which arises from the destruction of red blood cells by the parasite. This can lead to fatigue, weakness, and increased susceptibility to other infections, further compromising maternal health. Additionally, malaria can exacerbate pre-existing conditions such as HIV, leading to more severe outcomes. The burden of maternal morbidity due to malaria underscores the importance of effective prevention and treatment strategies.[5] Placental malaria, characterized by the sequestration of malaria-infected erythrocytes in the placenta, is a particularly severe form of the disease during pregnancy. This condition impairs the transfer of nutrients and oxygen from the mother to the fetus, leading to adverse pregnancy outcomes. Placental malaria is associated with increased risks of preterm birth, low birth weight, and stillbirth, which are major contributors to neonatal morbidity and mortality. Understanding the mechanisms of placental malaria is crucial for developing targeted interventions to mitigate its impact.[6-7]

In addition to its direct effects, malaria during pregnancy can lead to severe complications such as cerebral malaria, acute respiratory distress syndrome (ARDS), and multi-organ failure, all of which can be life-threatening. These complications significantly contribute to maternal mortality in malaria-endemic regions. The high rates of maternal mortality due to malaria highlight the need for comprehensive healthcare strategies that include early diagnosis, effective treatment, and robust preventive measures.[8-9] Preventive strategies for malaria in pregnancy have shown significant promise in reducing the incidence and severity of the disease. Intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp) is recommended by the WHO for pregnant women in areas of moderate to high malaria transmission. This involves administering therapeutic doses of sulfadoxine-pyrimethamine at scheduled antenatal visits, which has been shown to reduce maternal malaria episodes, anemia, and adverse pregnancy outcomes.[10-11] Insecticide-treated nets (ITNs) are another key preventive measure, providing a physical barrier against mosquito bites and reducing malaria transmission. The use of ITNs has been associated with substantial reductions in malaria incidence and mortality. Encouraging the consistent use of ITNs among pregnant women is essential for maximizing their protective benefits. Integrating ITNs with other preventive measures can enhance overall malaria control efforts.[12-13] Prompt diagnosis and effective treatment are critical components of malaria management during pregnancy. Artemisinin-based combination therapies (ACTs) are the first-line treatment for uncomplicated malaria in the second and third trimesters, while quinine is recommended during the first trimester. Timely treatment of malaria infections can prevent the progression to severe disease and reduce the risk of complications. Strengthening healthcare systems to ensure access to diagnostics and treatment is vital for improving maternal and fetal outcomes.[14-15] Despite the availability of

effective preventive and treatment options, several challenges hinder the control of malaria during pregnancy. These include issues related to access and adherence to preventive measures, drug resistance, and the need for continuous monitoring and evaluation of interventions. Addressing these challenges requires a multi-faceted approach that involves community engagement, health education, and robust healthcare infrastructure.[16-17]

Epidemiology

Malaria remains a major public health issue, particularly in tropical and subtropical regions, where transmission rates are highest. In 2020, the World Health Organization (WHO) reported that sub-Saharan Africa accounted for approximately 95% of global malaria cases and 96% of malaria deaths, underscoring the disproportionate impact of the disease in this region. Pregnant women are especially vulnerable to malaria, and the burden of the disease in this population is considerable.[18-19] The incidence of malaria during pregnancy varies significantly by region, depending on factors such as malaria transmission intensity, seasonality, and local healthcare infrastructure. In areas of high transmission, women can experience multiple infections during a single pregnancy. The WHO estimates that around 11 million pregnancies were exposed to malaria in 2020 alone, resulting in significant adverse outcomes for both mothers and their infants.[20-21] Plasmodium falciparum is the most prevalent and dangerous malaria species affecting pregnant women, particularly in sub-Saharan Africa. This species is responsible for the majority of severe malaria cases and deaths. Pregnant women are more susceptible to Plasmodium falciparum due to changes in their immune systems that make them less capable of fighting off the infection. Additionally, the parasite's ability to sequester in the placenta exacerbates the disease's impact on both maternal and fetal health.[22-23] The prevalence of malaria in pregnancy is influenced by several factors, including socio-economic status, access to healthcare, and the effectiveness of malaria control programs. Women in rural and impoverished areas often have limited access to preventive measures such as insecticide-treated nets (ITNs) and intermittent preventive treatment (IPTp), increasing their risk of infection. Furthermore, cultural practices and knowledge gaps about malaria prevention can hinder the uptake of these interventions.[24-25] Malaria in pregnancy contributes significantly to maternal morbidity and mortality. Pregnant women with malaria are more likely to develop severe anemia, which can lead to increased maternal mortality if left untreated. Severe malaria can also result in complications such as cerebral malaria and acute respiratory distress syndrome (ARDS), both of which are life-threatening conditions. These complications highlight the need for effective malaria prevention and management strategies targeted at pregnant women.[26-27]

The impact of malaria on pregnancy outcomes is profound. Malaria is a leading cause of preterm birth, low birth weight, and stillbirth in endemic regions. Placental malaria, where malaria-infected erythrocytes accumulate in the placenta, disrupts the transfer of nutrients and oxygen to the fetus, leading to intrauterine growth restriction (IUGR) and other adverse outcomes. Infants born to mothers with malaria are also at increased risk of neonatal death, emphasizing the intergenerational impact of the disease.[28-29] Effective malaria control measures are essential for reducing the incidence of malaria in pregnancy. Intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp) and the use of insecticide-treated nets (ITNs) are key interventions

recommended by the WHO. These measures have been shown to significantly reduce the incidence of malaria, maternal anemia, and adverse pregnancy outcomes. However, challenges such as drug resistance and variability in implementation coverage remain significant barriers to achieving widespread success.[30-31] The epidemiological patterns of malaria in pregnancy are also influenced by seasonality and climatic factors. Malaria transmission typically peaks during and after the rainy season when mosquito breeding conditions are optimal. This seasonality affects the timing and intensity of malaria interventions, requiring adaptive strategies to ensure pregnant women receive adequate protection throughout their pregnancies.[32-33] Monitoring and surveillance of malaria in pregnancy are crucial for understanding the disease's impact and guiding public health interventions. Data on malaria prevalence, intervention coverage, and pregnancy outcomes help inform policy decisions and resource allocation. Strengthening health systems to improve data collection and analysis is vital for effective malaria control and prevention efforts.[34-35]

Pathophysiology

Malaria during pregnancy presents a complex interplay of immunological, hematological, and physiological changes that significantly impact both maternal and fetal health. The pathophysiology of malaria in pregnancy primarily involves the interactions between Plasmodium falciparum, the most lethal malaria parasite, and the maternal host, particularly focusing on placental sequestration, immune modulation, and the resultant adverse outcomes.[36-37] One of the hallmark features of malaria in pregnancy is the sequestration of malaria-infected erythrocytes in the placenta. Plasmodium falciparum-infected red blood cells express a variant surface antigen known as VAR2CSA, which has a high affinity for chondroitin sulfate A (CSA) on placental syncytiotrophoblasts. This adhesion mechanism facilitates the accumulation of infected erythrocytes in the placenta, leading to placental malaria. The sequestration disrupts the normal architecture and function of the placenta, impairing nutrient and oxygen exchange between the mother and the fetus.[38-39] Pregnancy induces significant changes in the maternal immune system, characterized by a shift towards a more tolerant state to accommodate the developing fetus. This immunological modulation, while beneficial for fetal tolerance, reduces the efficacy of the maternal immune response against infections, including malaria. The maternal immune system's reduced capacity to clear malaria parasites allows for higher parasitemia levels and more severe manifestations of the disease. Additionally, the immune response to placental malaria involves local inflammation, with the release of pro-inflammatory cytokines such as TNF-alpha and IFN-gamma, which can further damage placental tissue and exacerbate adverse pregnancy outcomes.[40-41] Malaria in pregnancy is often associated with severe anemia, which results from the destruction of infected and uninfected red blood cells, impaired erythropoiesis, and increased splenic clearance of red blood cells. Anemia is a significant contributor to maternal morbidity, leading to fatigue, weakness, and increased susceptibility to other infections. Severe anemia can also exacerbate pre-existing conditions and increase the risk of maternal mortality.[42-43]

The accumulation of infected erythrocytes in the placenta triggers an inflammatory response, characterized by the infiltration of immune cells such as macrophages and monocytes. This inflammatory milieu can lead to the release of reactive oxygen species and other cytotoxic agents, causing placental tissue damage. The resulting placental insufficiency impairs the delivery of

essential nutrients and oxygen to the fetus, contributing to adverse outcomes such as intrauterine growth restriction (IUGR), low birth weight, and preterm birth. The disruption of placental function is a critical pathway through which malaria exerts its deleterious effects on fetal development.[44-45] Beyond the placenta, malaria during pregnancy can lead to systemic effects that further compromise maternal health. Severe malaria can manifest as cerebral malaria, acute respiratory distress syndrome (ARDS), acute kidney injury, and multi-organ failure. These severe complications arise from the widespread sequestration of infected erythrocytes in microvascular beds throughout the body, leading to tissue ischemia, organ dysfunction, and systemic inflammatory responses. The risk of such severe manifestations underscores the need for prompt diagnosis and effective treatment of malaria in pregnant women.[46-47] The pathophysiological mechanisms of malaria in pregnancy extend to the fetus, resulting in a range of adverse outcomes. Placental insufficiency due to malaria-induced damage can lead to fetal hypoxia and nutrient deprivation, contributing to IUGR, low birth weight, and preterm delivery. These conditions are associated with increased neonatal morbidity and mortality, including a higher risk of stillbirth and early neonatal death. Additionally, infants born to mothers with malaria are more susceptible to malaria infection themselves, as they may inherit a compromised immune status and have reduced levels of maternal antibodies.[48-49] Malaria during pregnancy often co-occurs with other infections, such as HIV, which can further complicate the disease course and outcomes. Co-infection with HIV increases the susceptibility to malaria and exacerbates the severity of the disease by further compromising the immune system. HIV-infected pregnant women are at higher risk of severe anemia, higher parasite loads, and increased mortality. The interaction between malaria and HIV highlights the need for integrated healthcare approaches to manage co-infections in pregnant women.[50-51] Intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp) aims to reduce parasite burden and prevent placental malaria. Insecticide-treated nets (ITNs) provide a physical barrier against mosquito bites, reducing malaria transmission. Prompt and effective treatment with artemisinin-based combination therapies (ACTs) is essential for managing malaria infections and preventing severe complications.[52-53]

Effects on Maternal Health

Malaria during pregnancy significantly impacts maternal health, contributing to a wide range of complications and increasing the risk of severe outcomes. These effects are multifaceted, involving hematological, immunological, and systemic changes that can profoundly affect a pregnant woman's well-being.[54] Anemia is one of the most common complications of malaria in pregnancy. The destruction of red blood cells by Plasmodium falciparum, combined with impaired erythropoiesis and increased splenic clearance of both infected and uninfected erythrocytes, leads to significant reductions in hemoglobin levels. Severe anemia can cause fatigue, weakness, dizziness, and shortness of breath. In pregnant women, anemia increases the risk of poor perinatal outcomes and can lead to maternal death if left untreated. The impact of anemia extends beyond immediate physical health, affecting the woman's ability to work and care for her family, thereby having broader socio-economic implications.[55-56] Placental malaria, resulting from the sequestration of malaria-infected erythrocytes in the placenta, can lead to a range of adverse maternal health outcomes. The inflammatory response triggered by placental malaria can cause placental dysfunction, reducing the efficiency of nutrient and oxygen transfer to the fetus. This

condition not only affects fetal development but also increases the mother's risk of complications such as pre-eclampsia and eclampsia, both of which are hypertensive disorders that can be life-threatening. Additionally, placental malaria has been associated with increased risks of maternal hemorrhage and infection during and after childbirth.[57-58] Malaria during pregnancy is associated with an increased risk of hypertensive disorders, particularly pre-eclampsia and eclampsia. Pre-eclampsia is characterized by high blood pressure and proteinuria and can lead to severe complications, including organ damage and fetal growth restriction. If pre-eclampsia progresses to eclampsia, the condition can cause seizures, which pose significant risks to both the mother and the fetus. The exact mechanisms linking malaria to these hypertensive disorders are not fully understood but are thought to involve placental inflammation and endothelial dysfunction caused by malaria infection.[59-60]

In some cases, malaria in pregnancy can progress to severe malaria, which includes complications such as cerebral malaria, acute respiratory distress syndrome (ARDS), acute kidney injury, and multi-organ failure. Cerebral malaria, characterized by impaired consciousness and seizures, can be fatal if not promptly treated. ARDS, resulting from severe inflammation and fluid accumulation in the lungs, leads to respiratory failure and requires intensive medical intervention. These severe forms of malaria are associated with high mortality rates and necessitate immediate and effective medical treatment to prevent death.[61-62] Malaria is a significant contributor to maternal mortality in endemic regions. The disease can lead to direct causes of death, such as severe anemia, cerebral malaria, and multi-organ failure, as well as indirect causes, including increased vulnerability to other infections and complications during childbirth. Pregnant women with malaria are at higher risk of maternal death, particularly in settings with limited access to healthcare and inadequate medical infrastructure. Addressing malaria in pregnancy is therefore critical for reducing maternal mortality rates and improving maternal health outcomes.[63-64] Malaria during pregnancy often coexists with other infections and conditions, such as HIV, tuberculosis, and malnutrition. Co-infection with HIV, for instance, exacerbates the severity of malaria and increases the risk of adverse outcomes. HIV-positive pregnant women with malaria are more likely to experience higher parasite loads, severe anemia, and increased mortality. The interaction between malaria and other comorbidities complicates the clinical management of pregnant women and underscores the need for integrated healthcare approaches to address multiple health challenges simultaneously.[65-66]

The health impacts of malaria in pregnancy extend beyond physical morbidity. The disease can also have significant psychological effects, including anxiety and depression, particularly when it leads to severe illness or adverse pregnancy outcomes. Moreover, the socio-economic impact of malaria on pregnant women and their families is substantial. Women who are ill with malaria may be unable to work or care for their families, leading to lost income and increased financial strain. This socio-economic burden highlights the importance of effective malaria prevention and treatment strategies to support the overall well-being of pregnant women and their communities.[67-68] Effective preventive and therapeutic interventions are essential for mitigating the adverse effects of malaria on maternal health. Intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp) has been shown to reduce the incidence of maternal malaria and related complications. The use of insecticide-treated nets (ITNs) provides a crucial preventive measure by protecting pregnant

women from mosquito bites. Prompt diagnosis and treatment with artemisinin-based combination therapies (ACTs) are vital for managing malaria infections and preventing severe outcomes. Ensuring access to these interventions is critical for improving maternal health in malaria-endemic regions.[69-70] Access to quality healthcare is a key determinant of maternal health outcomes in the context of malaria. Women in rural and low-resource settings often face barriers to accessing preventive and treatment services, including limited availability of healthcare facilities, shortages of trained healthcare providers, and financial constraints. Strengthening healthcare infrastructure, enhancing healthcare worker training, and addressing socio-economic barriers are essential steps towards improving access to malaria prevention and treatment for pregnant women. Ensuring that all pregnant women have access to timely and effective healthcare is critical for reducing the burden of malaria on maternal health.[71-72]

Maternal Mortality

Malaria during pregnancy is a significant contributor to maternal mortality, particularly in regions where the disease is endemic. The interplay of direct and indirect effects of malaria significantly increases the risk of maternal death, highlighting the urgent need for effective prevention, timely diagnosis, and appropriate treatment strategies. Understanding the factors contributing to maternal mortality due to malaria is essential for developing targeted interventions to save the lives of pregnant women.[73] Malaria-induced hemolysis and the destruction of red blood cells lead to severe anemia, which is a major cause of maternal mortality. Severe anemia reduces the oxygen-carrying capacity of the blood, leading to hypoxia, which can result in heart failure and death if not treated promptly. Anemic pregnant women are also more susceptible to hemorrhage during childbirth, increasing the risk of death.[74] This severe form of malaria is characterized by neurological symptoms, including altered consciousness, seizures, and coma. Cerebral malaria can lead to permanent brain damage or death if not treated rapidly and effectively. Pregnant women are particularly vulnerable due to their altered immune responses, making them more susceptible to severe disease.[75] **Acute Respiratory Distress Syndrome (ARDS)**, resulting from severe inflammation and fluid accumulation in the lungs, can cause respiratory failure. Malaria-induced ARDS requires intensive medical intervention and can be fatal, especially in settings with limited healthcare resources.[76] Severe malaria can cause dysfunction in multiple organ systems, including the liver, kidneys, and cardiovascular system. This multi-organ failure results from widespread sequestration of infected erythrocytes in the microvasculature, leading to ischemia and organ damage. The rapid progression to multi-organ failure is often fatal without immediate and comprehensive medical care.[77]

Indirect Causes of Maternal Mortality

Malaria-induced anemia and immune suppression increase the susceptibility of pregnant women to other infections, such as bacterial and viral infections. Concurrent infections can complicate the clinical management of malaria and lead to increased mortality. Malaria can exacerbate complications during labor and delivery, including pre-eclampsia, eclampsia, and hemorrhage. These complications are leading causes of maternal death in malaria-endemic regions. Malaria-related placental insufficiency and anemia further complicate childbirth, increasing the risk of

adverse outcomes. HIV-positive pregnant women with malaria face higher mortality rates due to the compounded effects of both infections. HIV compromises the immune system, reducing the body's ability to fight off malaria and increasing the severity of the disease. Co-infected women are more likely to experience severe anemia, higher parasite loads, and increased maternal mortality.[78-79] Pregnant women in rural and low-resource settings often lack access to adequate healthcare services, including preventive measures, timely diagnosis, and effective treatment for malaria. Limited access to antenatal care (ANC) services means that many cases of malaria go undetected and untreated, increasing the risk of severe disease and death. In many malaria-endemic regions, healthcare facilities are under-resourced and understaffed. The lack of essential medical supplies, diagnostic tools, and trained healthcare providers hinder effective management of malaria in pregnancy. This inadequate healthcare infrastructure contributes to higher maternal mortality rates. Financial constraints, transportation challenges, and cultural practices can prevent pregnant women from seeking and receiving timely medical care for malaria. Socio-economic barriers also impact the consistent use of preventive measures such as insecticide-treated nets (ITNs) and intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp).[80-81]

Intermittent Preventive Treatment (IPTp) with sulfadoxine-pyrimethamine is recommended by the World Health Organization (WHO) for all pregnant women in malaria-endemic areas. IPTp has been shown to reduce the incidence of malaria, severe anemia, and adverse pregnancy outcomes, thereby decreasing maternal mortality. The use of **Insecticide-treated Nets (ITNs)** is a crucial preventive measure, providing a physical barrier against mosquito bites and reducing malaria transmission. Ensuring widespread distribution and consistent use of ITNs among pregnant women can significantly lower the risk of malaria and associated mortality. Early diagnosis and treatment of malaria are essential for preventing severe disease and complications. Artemisinin-based combination therapies (ACTs) are the first-line treatment for malaria in pregnancy. Ensuring access to these effective treatments and strengthening healthcare systems to provide timely and accurate diagnosis are critical steps in reducing maternal mortality. Addressing co-infections and comorbidities through integrated healthcare approaches can improve maternal outcomes. Providing comprehensive antenatal care that includes screening and treatment for malaria, HIV, and other infections is essential for reducing the overall burden of disease and maternal mortality.[82-83]

Effects on Pregnancy Outcomes

Malaria during pregnancy has profound and multifaceted effects on pregnancy outcomes, posing significant risks to both the mother and the fetus. The adverse outcomes associated with malaria in pregnancy are due to a combination of direct effects of the malaria infection and indirect effects mediated through maternal health complications. Understanding these effects is crucial for developing effective interventions to mitigate the risks and improve maternal and fetal health outcomes. Intrauterine growth restriction (IUGR) is a common complication of malaria during pregnancy. Placental malaria, characterized by the sequestration of Plasmodium falciparum-infected erythrocytes in the placenta, leads to inflammation and structural damage to the placental tissue. This disruption impairs the placenta's ability to deliver adequate nutrients and oxygen to the developing fetus, resulting in restricted fetal growth. Infants born with IUGR are at increased

risk of perinatal morbidity and mortality and may face long-term developmental challenges. Malaria in pregnancy is a leading cause of low birth weight (LBW), defined as a birth weight of less than 2,500 grams. LBW can result from IUGR or preterm birth, both of which are associated with malaria. Placental insufficiency due to malaria infection is a major factor contributing to LBW. Infants with LBW have higher rates of neonatal morbidity and mortality and are at increased risk of chronic health issues later in life, such as impaired cognitive development and susceptibility to infections.[84-85]

Preterm birth, defined as delivery before 37 weeks of gestation, is another significant adverse outcome of malaria during pregnancy. Malaria-induced inflammation and placental damage can trigger preterm labor. Preterm infants are at higher risk of respiratory distress syndrome, sepsis, and other neonatal complications. The long-term health prospects of preterm infants are also compromised, with potential for ongoing developmental and health challenges. Stillbirth, the death of a fetus at or after 20 weeks of gestation, is a devastating outcome associated with malaria in pregnancy. Placental malaria can lead to severe fetal hypoxia and nutrient deprivation, resulting in fetal death. The risk of stillbirth is particularly high in cases of severe malaria and in regions with high malaria transmission rates. Addressing malaria in pregnancy is crucial for reducing the incidence of stillbirths and improving overall pregnancy outcomes. Malaria during pregnancy significantly increases the risk of neonatal mortality. Infants born to mothers with malaria are more likely to be preterm, have LBW, or suffer from IUGR, all of which contribute to higher rates of neonatal death. Additionally, the compromised health status of these infants makes them more vulnerable to other infections and complications during the neonatal period. Effective prevention and management of malaria in pregnancy are vital for reducing neonatal mortality rates.[86-87]

Congenital malaria occurs when malaria parasites are transmitted from the mother to the fetus during pregnancy. Although relatively rare, congenital malaria can cause significant neonatal morbidity. Symptoms in affected infants may include fever, irritability, feeding difficulties, anemia, and hepatosplenomegaly. Early diagnosis and treatment are essential for managing congenital malaria and preventing severe outcomes. The adverse effects of malaria on pregnancy outcomes are closely linked to maternal health complications. Severe maternal anemia, pre-eclampsia, and eclampsia, as well as other complications resulting from malaria, directly impact fetal development and pregnancy outcomes. Ensuring maternal health through effective malaria prevention and treatment is essential for improving pregnancy outcomes. The impact of malaria in one pregnancy can extend to subsequent pregnancies. Women who experience malaria during pregnancy may have an increased risk of adverse outcomes in future pregnancies due to potential long-term effects on maternal health. Chronic anemia, immune suppression, and other complications from previous malaria infections can contribute to poor outcomes in subsequent pregnancies. Comprehensive care and follow-up for women who have had malaria in pregnancy are crucial for mitigating these risks. The adverse pregnancy outcomes associated with malaria have significant socio-economic implications. Families may face increased medical expenses, loss of income due to maternal or neonatal illness, and long-term care costs for children with developmental challenges. The broader community also bears the economic burden of increased healthcare needs and reduced productivity. Addressing malaria in pregnancy is not only a health priority but also a socio-economic imperative for communities in endemic regions.[88-89]

Prevention and Management

Intermittent Preventive Treatment (IPTp) is a key malaria control strategy specifically designed to protect pregnant women in malaria-endemic regions from the adverse effects of malaria. The strategy involves administering anti-malarial medication at specified intervals during pregnancy, regardless of whether the woman is symptomatic or asymptomatic. IPTp is aimed at reducing the incidence of malaria infection, preventing severe complications, and improving maternal and fetal health outcomes. The World Health Organization (WHO) recommends IPTp with sulfadoxine-pyrimethamine (SP) as the standard regimen for malaria prevention in pregnant women. IPTp is generally administered during the second and third trimesters of pregnancy. The exact timing and number of doses may vary based on national guidelines and local malaria transmission patterns. The standard dose of SP is a single oral dose of 1500 mg of sulfadoxine and 75 mg of pyrimethamine. This dosage is intended to provide effective prophylaxis against malaria. IPTp is typically administered at least once per trimester, starting from the second trimester. In high-transmission areas, additional doses may be recommended based on local guidelines.[86]

Insecticide-treated nets (ITNs) are a cornerstone of malaria prevention strategies in endemic regions. These nets are designed to reduce malaria transmission by providing a barrier between humans and mosquitoes, thereby preventing mosquito bites that can transmit the Plasmodium parasites responsible for malaria. ITNs are effective, cost-efficient, and easy-to-implement tools that play a crucial role in malaria control and elimination efforts. Mosquitoes that come into contact with the insecticide on the net are killed or repelled. This reduces the number of mosquitoes that can transmit malaria parasites. ITNs can deter mosquitoes from landing on or near the sleeping area, reducing the likelihood of bites. The insecticide on the net can also repel mosquitoes, keeping them away from the netted area. By decreasing the number of mosquitoes around households, ITNs contribute to lower vector densities, which in turn reduces malaria transmission within the community. Achieving high coverage and access to ITNs can be challenging, particularly in remote or underserved areas. Ensuring that all households have access to ITNs and that they are used consistently is crucial for maximizing their impact. Effective malaria prevention requires that ITNs are used correctly. Issues such as improper hanging, damage to the nets, and inadequate re-treatment (for non-LLINs) can reduce their effectiveness. Education on proper use and maintenance is essential. The development of insecticide resistance among mosquito populations can impact the effectiveness of ITNs. Monitoring resistance patterns and adapting strategies to address resistance are important for maintaining the efficacy of ITNs. Socio-economic factors such as poverty, lack of awareness, and cultural practices can influence ITN use and acceptance. Addressing these factors through community engagement and education is important for improving ITN uptake and adherence.[87]

Prompt diagnosis and treatment of malaria are critical components of effective malaria control and management. Early identification of malaria cases and timely initiation of appropriate treatment significantly reduce the risk of severe disease, complications, and transmission. This approach not only improves individual health outcomes but also contributes to broader public health efforts to control and eliminate malaria. Malaria, particularly if caused by Plasmodium falciparum, can rapidly progress from mild symptoms to severe forms of the disease. Early diagnosis allows for

timely treatment, which is crucial in preventing the progression to severe malaria, including complications like cerebral malaria, severe anemia, and organ failure. Early diagnosis and treatment reduce the number of infectious cases in the community, thereby decreasing the overall transmission of malaria. This helps to limit the spread of the parasite and control outbreaks. Timely diagnosis helps prevent complications such as severe anemia, which can lead to maternal and neonatal mortality. Early treatment can mitigate the risks associated with malaria in pregnancy, including adverse pregnancy outcomes like low birth weight and stillbirth. Early diagnosis and treatment are cost-effective, reducing the need for more expensive, intensive care and preventing the economic burden associated with severe malaria cases.[88]

Microscopic examination of blood smears remains the gold standard for malaria diagnosis. It involves staining and examining a blood sample under a microscope to identify and quantify malaria parasites. While highly accurate, microscopy requires skilled personnel and appropriate laboratory infrastructure. **Rapid Diagnostic Tests (RDTs)** detect specific malaria antigens in blood samples and provide results quickly, typically within 15-20 minutes. They are especially useful in settings with limited laboratory facilities and are recommended for initial diagnosis in many malaria-endemic regions. RDTs are less dependent on laboratory infrastructure and can be used at the point of care. **Polymerase Chain Reaction (PCR)** is a highly sensitive and specific method for detecting malaria parasites by amplifying their DNA. It is useful for confirming diagnoses and detecting low-level infections but is not commonly used in routine clinical settings due to its complexity and cost. In some settings, a combination of microscopy and RDTs is used to enhance diagnostic accuracy and ensure reliable results. This approach is particularly useful for confirming cases and addressing limitations of individual diagnostic methods. The World Health Organization (WHO) recommends artemisinin-based combination therapies (ACTs) as the first-line treatment for uncomplicated malaria. ACTs combine an artemisinin derivative with a partner drug to enhance efficacy and reduce the risk of drug resistance. Common ACTs include artemether-lumefantrine and artesunate-amodiaquine. Severe malaria requires prompt and effective treatment to prevent mortality and complications. Intravenous (IV) or intramuscular (IM) administration of artesunate is the recommended treatment for severe malaria. Following initial parenteral therapy, patients are typically switched to oral ACTs to complete the treatment course. Treatment of malaria in pregnant women requires special considerations to ensure safety for both the mother and the fetus. In the first trimester, quinine plus clindamycin is often used. In the second and third trimesters, ACTs like artemether-lumefantrine are generally recommended, following WHO guidelines. Monitoring and managing drug resistance is critical for maintaining the effectiveness of malaria treatments. Resistance patterns should be regularly assessed, and treatment guidelines should be adapted based on emerging data to ensure continued efficacy.[89]

Conclusion

Effective management of malaria requires a comprehensive approach encompassing prevention, prompt diagnosis, and treatment. Each component plays a crucial role in reducing the burden of malaria, improving health outcomes, and contributing to the broader goal of malaria elimination. **Prevention** strategies, such as Insecticide-Treated Nets (ITNs) and Intermittent Preventive Treatment (IPTp), are essential in reducing malaria incidence and protecting vulnerable

populations. ITNs provide a physical barrier against mosquito bites and reduce malaria transmission, while IPTp helps to prevent malaria in pregnant women, thereby mitigating risks to both maternal and fetal health. Both strategies have demonstrated significant effectiveness in lowering malaria cases and improving health outcomes, though challenges related to coverage, resistance, and adherence must be addressed.

Prompt diagnosis and treatment are critical in managing malaria effectively. Early detection through diagnostic tools such as microscopy, Rapid Diagnostic Tests (RDTs), and Polymerase Chain Reaction (PCR) enables timely and appropriate treatment, which is crucial in preventing severe disease and reducing transmission. Artemisinin-based combination therapies (ACTs) remain the standard treatment for uncomplicated malaria, while severe cases require more intensive care. Ensuring accurate diagnosis, adherence to treatment protocols, and addressing barriers to access and quality are essential for optimizing treatment outcomes. The integration of these components into a cohesive malaria control strategy is vital for achieving and sustaining progress in malaria reduction. Strengthening healthcare systems, improving access to diagnostic and treatment services, and engaging communities in malaria prevention efforts are key to overcoming existing challenges. Continuous research, monitoring, and adaptation of strategies based on emerging evidence and resistance patterns will enhance the effectiveness of malaria control programs.

References

1. Uneke CJ. Impact of placental Plasmodium falciparum malaria on pregnancy and perinatal outcome in sub-Saharan Africa: part III: placental malaria, maternal health, and public health. The Yale journal of biology and medicine. 2008;81(1):1.
2. Gontie GB, Wolde HF, Baraki AG. Prevalence and associated factors of malaria among pregnant women in Sherkole district, Benishangul Gumuz regional state, West Ethiopia. BMC Infectious Diseases. 2020; 20:1-8.
3. Obeagu EI, Agreen FC. Anaemia among pregnant women: A review of African pregnant teenagers. J Pub Health Nutri. 2023; 6 (1). 2023;138. links/63da799664fc860638054562/Anaemia-among-pregnant-women-A-review-of-African-pregnant-teenagers.pdf.
4. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 2016;3(3):10-8. links/5710fae108ae846f4ef05afb/ERYTHROPOIETIN-IN-THE-ANAEMIAS-OF-PREGNANCY-A-REVIEW.pdf.
5. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala PU, Agu CC. Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria. J Res Med Dent Sci. 2021;9(4):145-8. links/608a6728a6fdccaebdf52d94/Assessment-of-Haematological-Changes-in-Pregnant-Women-of-Ido-Ondo.pdf.
6. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 ;6(2):10-3. http://irmhs.com/index.php/irmhs/article/view/111.
7. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis,

Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.

8. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. Evaluation of Protein C, Protein S and Fibrinogen of Pregnant Women with Malaria in Owerri Metropolis. Madonna University journal of Medicine and Health Sciences. 2022;2(2):1-9.
9. Bonilla FA, Oettgen HC. Adaptive immunity. Journal of Allergy and Clinical Immunology. 2010;125(2): S33-40.
10. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. EVALUATION OF PROTEIN C, PROTEIN S AND FIBRINOGEN OF PREGNANT WOMEN WITH MALARIA IN OWERRI METROPOLIS. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022;2(2):1-9.
11. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.
12. Feeney ME. The immune response to malaria in utero. Immunological reviews. 2020 ;293(1):216-229.
13. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine. 2023;102(46): e36166.
14. Obeagu EI, Chijioke UO, Ekelozie IS. Malaria rapid diagnostic test (RDTs). Ann Clin Lab Res. 2018;6(4):275.
15. Ogomaka IA, Obeagu EI. Methods of Breast Feeding as Determinants of Malaria Infections among Babies in IMO State, Nigeria. International Journal of Medical Science and Dental Research. 2019;2(01):17-24.
16. Obeagu EI, Ikpenwa JN, Chukwueze CM, Obeagu GU. Evaluation of protein C, protein S and fibrinogen of pregnant women in Owerri Metropolis. Madonna University Journal of Medicine and Health Sciences. 2022;2(1):292-8. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/57.
17. Obeagu EI, Obeagu GU, Adepoju OJ. Evaluation of haematological parameters of pregnant women based on age groups in Olorunsogo road area of Ido, Ondo state. J. Bio. Innov11 (3). 2022:936-941.
18. Obeagu EI, Obeagu GU, Egba SI, Emeka-Obi OR. Combatting Anemia in Pediatric Malaria: Effective Management Strategies. Int. J. Curr. Res. Med. Sci. 2023;9(11):1-7.
19. Hassan AO, Oso OV, Obeagu EI, Adeyemo AT. Malaria Vaccine: Prospects and Challenges. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022;2(2):22-40.
20. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-9.
21. Moya-Alvarez V, Abellana R, Cot M. Pregnancy-associated malaria and malaria in infants: an old problem with present consequences. Malaria journal. 2014; 13:1-10.

22. Obeagu EI. An update on utilization of antenatal care among pregnant Women in Nigeria. Int. J. Curr. Res. Chem. Pharm. Sci. 2022;9(9): 21-6.DOI: 10.22192/ijcrcps.2022.09.09.003
23. Okoroiwu IL, Obeagu EI, Obeagu GU. Determination of clot retraction in preganant women attending antenatal clinic in federal medical centre Owerri, Nigeria. Madonna University Journal of Medicine and Health Sciences. 2022;2(2):91-97. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/67.
24. Obeagu EI, Hassan AO, Adepoju OJ, Obeagu GU, Okafor CJ. Evaluation of Changes in Haematological Parameters of Pregnant Women Based on Gestational Age at Olorunsogo Road Area of Ido, Ondo State. Nigeria. Journal of Research in Medical and Dental Science. 2021;9(12):462-.links/61b1e32f0c4bfb675178bfa7/Evaluation-of-Changes-in-Haematological-Parameters-of-Pregnant-Women-Based-on-Gestational-Age-at-Olorunsogo-Road-Area-of-Ido-Ondo-State-Nigeria.pdf.
25. Anyiam AF, Obeagu EI, Obi E, Omosigho PO, Irondi EA, Arinze-Anyiam OC, Asiyah MK. ABO blood groups and gestational diabetes among pregnant women attending University of Ilorin Teaching Hospital, Kwara State, Nigeria. International Journal of Research and Reports in Hematology. 2022 Jun 21;5(2):113-121.
26. Obeagu EI. Gestational Thrombocytopaenia. J Gynecol Women's Health. 2023;25(3):556163. links/64b01aa88de7ed28ba95fccb/Gestational-Thrombocytopaenia.pdf.
27. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
28. Dobaño C, Berthoud T, Manaca MN, Nhabomba A, Guinovart C, Aguilar R, Barbosa A, Groves P, Rodríguez MH, Jimenez A, Quimice LM. High production of pro-inflammatory cytokines by maternal blood mononuclear cells is associated with reduced maternal malaria but increased cord blood infection. Malaria Journal. 2018; 17:1-3.
29. Obeagu EI, Busari AI, Uduchi IO, Ogomaka IA, Ibekwe AM, Vincent CC, Chijioke UO, Okafor CJ, Okoroiwu HU, Adike CN. Age-Related Haematological Variations in Patients with Asymptomatic Malaria in Akure, Ondo State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(42B):218-24.
30. Ogomaka IA, Obeagu EI. Malaria in Pregnancy Amidst Possession of Insecticide Treated Bed Nets (ITNs) in Orlu LGA of Imo State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(41B):380-386.
31. Ogbonna CO, Obeagu EI, Ufelle SA, Ogbonna LN. Evaluation of haematological alterations in children infected by Plasmodium falciparum Species in Enugu, Enugu State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(1):38-45.
32. Appay V. The physiological role of cytotoxic CD4+ T-cells: the holy grail? Clinical & Experimental Immunology. 2004;138(1):10-13.
33. Okorie HM, Obeagu EI, Obarezi HC, Anyiam AF. Assessment of some inflammatory cytokines in malaria infected pregnant women in Imo State Nigeria. International Journal of Medical Science and Dental Research. 2019;2(1):25-36.

34. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of some haematological parameters in malaria infected pregnant women in Imo state Nigeria. Int. J. Curr. Res. Biol. Med. 2018;3(9):1-4.
35. Nwosu DC, Obeagu EI, Ezenwuba C, Agu GC, Amah H, Ozims SJ, Nwanjo HU, Edward A, Izuchukwu IF, Amadike JN, Nwagwu AJ. Antioxidant status of children with Plasmodium falciparum malaria in Owerri municipal council of Imo state. Int. J. Curr. Res. Chem. Pharm. Sci. 2016;3(8):40-46.
36. Harrington WE, Kakuru A, Jagannathan P. Malaria in pregnancy shapes the development of foetal and infant immunity. Parasite immunology. 2019;41(3): e12573.
37. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. Annals of Clinical and Laboratory Research. 2017;5(4):206.
38. Anyiam AF, Arinze-Anyiam OC, Omosigho PO, Ibrahim M, Irondi EA, Obeagu EI, Obi E. Blood Group, Genotype, Malaria, Blood Pressure and Blood Glucose Screening Among Selected Adults of a Community in Kwara State: Implications to Public Health. Asian Hematology Research Journal. 2022;6(3):9-17.
39. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15.
40. Offie DC, Ibekwe AM, Agu CC, Esimai BN, Okpala PU, Obeagu EI, Ufelle SA, Ogbonna LN. Fibrinogen and C-Reactive Protein Significance in Children Infected by Plasmodium falciparum Species in Enugu, Enugu State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(15):1-8.
41. Obeagu EI, Ogunnaya FU. PREGNANCYINDUCED HAEMATOLOGICAL CHANGES: A KEY TO MARTERNAL AND CHILD HEALTH. European Journal of Biomedical. 2023;10(8):42-43. links/64c890bddb38b20d6dad2c5c/PREGNANCY-INDUCED-HAEMATOLOGICAL-CHANGES-A-KEY-TO-MARTERNAL-AND-CHILD-HEALTH.pdf
42. Obeagu EI, Ofodile AC, Okwuanaso CB. A review of urinary tract infections in pregnant women: Risks factors. J Pub Health Nutri. 2023; 6 (1). 2023; 137:26-35. links/63c3a9116fe15d6a571e8bba/A-review-of-urinary-tract-infections-in-pregnant-women-Risks-factors.pdf.
43. Obeagu EI, Obeagu GU, Musiimenta E. Post partum haemorrhage among pregnant women: Update on risks factors. Int. J. Curr. Res. Med. Sci. 2023;9(2): 14-17.DOI: 10.22192/ijcrms.2023.09.02.003
44. Obeagu EI, Obeagu GU, Ogunnaya FU. Deep vein thrombosis in pregnancy: A review of prevalence and risk factors. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(8): 14-21.DOI: 10.22192/ijcrcps.2023.10.08.002
45. Arama C, Quin JE, Kouriba B, Östlund Farrants AK, Troye-Blomberg M, Doumbo OK. Epigenetics and malaria susceptibility/protection: A missing piece of the puzzle. Frontiers in Immunology. 2018; 9:1733.

46. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of some haematological parameters in malaria infected pregnant women in Imo state Nigeria. Int. J. Curr. Res. Biol. Med. 2018;3(9): 1-4.DOI: 10.22192/ijcrbm.2018.03.09.001
47. Onyenweaku FC, Amah HC, Obeagu EI, Nwandikor UU, Onwuasoanya UF. Prevalence of asymptomatic bacteriuria and its antibiotic susceptibility pattern in pregnant women attending private ante natal clinics in Umuahia Metropolitan. Int J Curr Res Biol Med. 2017;2(2): 13-23.DOI: 10.22192/ijcrbm.2017.02.02.003
48. Okoroiwu IL, Chinedu-Madu JU, Obeagu EI, Vincent CC, Ochiabuto OM, Ibekwe AM, Amaechi CO, Agu CC, Anoh NV, Amadi NM. Evaluation of Iron Status, Haemoglobin and Protein Levels of Pregnant Women in Owerri Metropolis. Journal of Pharmaceutical Research International. 2021;33(27A):36-43.
49. Obeagu EI, Njar VE, Obeagu GU. Infertility: Prevalence and Consequences. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(7):43-50.
50. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Evaluation of levels of some inflammatory cytokines in preeclamptic women in owerri. Journal of Pharmaceutical Research International. 2021;33(42A):53-65.
51. Broen K, Brustoski K, Engelmann I, Luty AJ. Placental Plasmodium falciparum infection: causes and consequences of in utero sensitization to parasite antigens. Molecular and biochemical parasitology. 2007;151(1):1-8.
52. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of coagulation parameters in malaria infected pregnant women in Imo state, Nigeria. International Journal of Current Research in Medical Sciences. 2018;4(9):41-49.
53. Ogbonna LN, Ezeoru VC, Ofodile AC, Ochiabuto OM, Obi-Ezeani CN, Okpala PU, Okafor CJ, Obeagu GU, Busari AI, Obeagu EI. Gender Based Variations of Haematological Parameters of Patients with Asymptomatic Malaria in Akure, Ondo State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(8):75-80.
54. Eberendu IF, Ozims SJ, Agu GC, Amah HC, Obasi CC, Obioma-Elemba JE, Ihekaire DE, Ibanga IE, Amah CC, Obeagu EI, Nwosu DC. Impact of human activities on the breeding of mosquitoes of human disease in Owerri metropolis, Imo state. Int J Adv Res Biol Sci IJARBS. 2017;4(12):98-106.
55. Obeagu EI, Ofodile AC, Okwuanaso CB. A review on socio economic and behavioral aspects of malaria and its control among children under 5 years of age in Africa. J Pub Health Nutri. 2023; 6 (1): 136.
56. Djontu JC, Siewe Siewe S, Mpeke Edene YD, Nana BC, Chomga Foko EV, Bigoga JD, Leke RF, Megnekou R. Impact of placental Plasmodium falciparum malaria infection on the Cameroonian maternal and neonate's plasma levels of some cytokines known to regulate T cells differentiation and function. Malaria journal. 2016; 15:1-1.
57. Obeagu EI, Faduma MH, Uzoma G. Ectopic Pregnancy: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4): 40-4.DOI: 10.22192/ijcrcps.2023.10.04.004
58. Obeagu EI, Gamade SM, Obeagu GU. The roles of Neutrophils in pregnancy. Int. J. Curr. Res. Med. Sci. 2023;9(5): 31-35.DOI: 10.22192/ijcrms.2023.09.05.005
59. Obeagu EI, Obeagu GU. Molar Pregnancy: Update of prevalence and risk factors. Int. J. Curr. Res. Med. Sci. 2023;9(7): 25-28.DOI: 10.22192/ijcrms.2023.09.07.005

60. Kabyemela E, Gonçalves BP, Prevots DR, Morrison R, Harrington W, Gwamaka M, Kurtis JD, Fried M, Duffy PE. Cytokine profiles at birth predict malaria severity during infancy. PloS one. 2013;8(10):e77214.
61. Ibebuike JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC, Nwanjo HU, Agu GC, Ezenwuba CO, Nwagu SA, Akujuobi AU. Barriers to utilization of maternal health services in southern senatorial district of Cross Rivers state, Nigeria. International Journal of Advanced Multidisciplinary Research. 2017;4(8): 1-9.DOI: 10.22192/ijamr.2017.04.08.001
62. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
63. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of coagulation parameters in malaria infected pregnant women in Imo state, Nigeria. International Journal of Current Research in Medical Sciences. 2018;4(9): 41-9.DOI: 10.22192/ijcrms.2018.04.09.006
64. Obeagu EI, Obeagu GU. Postpartum haemorrhage among women delivering through spontaneous vaginal delivery: Prevalence and risk factors. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(8): 22-6.DOI: 10.22192/ijcrcps.2023.10.08.003
65. Obeagu E, Eze RI, Obeagu EI, Nnatuanya IN, Dara EC. ZINC LEVEL IN APPARENTLY PREGNANT WOMEN IN URBAN AREA. Madonna University journal of Medicine and Health Sciences. 2022;2(1):134-48. https://www.journal.madonnauniversity.edu.ng/index.php/medicine/article/view/40.
66. Ogomaka IA, Obeagu EI. Malaria in Pregnancy Amidst Possession of Insecticide Treated Bed Nets (ITNs) in Orlu LGA of Imo State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(41B):380-386.
67. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. SICKLE CELL ANAEMIA: A GESTATIONAL ENIGMA. migration. 2023; 17:18.
68. Harrington WE, Kakuru A, Jagannathan P. Malaria in pregnancy shapes the development of foetal and infant immunity. Parasite immunology. 2019;41(3):e12573.
69. Ifeanyi OE, Uzoma OG. A review on erythropietin in pregnancy. J. Gynecol. Womens Health. 2018;8(3):1-4. https://www.academia.edu/download/56538560/A_Review_on_Erythropietin_in_Pregnancy.pdf.
70. Ifeanyi OE. A review on pregnancy and haematology. Int. J. Curr. Res. Biol. Med. 2018;3(5): 26-8.DOI: 10.22192/ijcrbm.2018.03.05.006
71. Nwosu DC, Nwanjo HU, Obeagu EI, Ibebuike JE, Ezeama MC. Ihekireh. Changes in liver enzymes and lipid profile of pregnant women with malaria in Owerri, Nigeria. International Journal of Current Research and Academic Review. 2015;3(5):376-383.
72. Ibebuike JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC, Nwanjo HU, Agu GC, Ezenwuba CO, Nwagu SA, Akujuobi AU. Factors that influence women's utilization of primary health care services in Calabar Cros river state, Nigeria. Int. J. Curr. Res. Chem. Pharm. Sci. 2017;4(7):28-33.

73. Elemchukwu Q, Obeagu EI, Ochei KC. Prevalence of Anaemia among Pregnant Women in Braithwaite Memorial Specialist Hospital (BMSH) Port Harcourt. IOSR Journal of Pharmacy and Biological Sciences. 2014;9(5):59-64.
74. Natama HM, Moncunill G, Rovira-Vallbona E, Sanz H, Sorgho H, Aguilar R, Coulibaly-Traoré M, Somé MA, Scott S, Valéa I, Mens PF. Modulation of innate immune responses at birth by prenatal malaria exposure and association with malaria risk during the first year of life. BMC medicine. 2018; 16:1-5.
75. Akandinda M, Obeagu EI, Katonera MT. Non Governmental Organizations and Women's Health Empowerment in Uganda: A Review. Asian Research Journal of Gynaecology and Obstetrics. 2022;8(3):12-26.
76. Gamde MS, Obeagu EI. IRON DEFICIENCY ANAEMIA: ENEMICAL TO PREGNANCY. European Journal of Biomedical. 2023;10(9):272-275. links/64f63358827074313ffaae7b/IRON-DEFICIENCY-ANAEMIA-ENEMICAL-TO-PREGNANCY.pdf.
77. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Evaluation of levels of some inflammatory cytokines in preeclamptic women in owerri. Journal of Pharmaceutical Research International. 2021;33(42A):53-65.
78. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Studies of Some Haemostatic Variables in Preeclamptic Women in Owerri, Imo State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(42B):39-48.
79. Obeagu EI, Obeagu GU. Postpartum haemorrhage among women delivering through spontaneous vaginal delivery: Prevalence and risk factors. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(8):22-26.
80. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023;6(2):10-13.
81. Mutabingwa TK, Bolla MC, Li JL, Domingo GJ, Li X, Fried M, Duffy PE. Maternal malaria and gravidity interact to modify infant susceptibility to malaria. PLoS medicine. 2005;2(12):e407.
82. Gamble C, Ekwaru PJ, Garner P, Ter Kuile FO. Insecticide-treated nets for the prevention of malaria in pregnancy: a systematic review of randomised controlled trials. PLoS medicine. 2007;4(3):e107.
83. Okoko BJ, Enwere G, Ota MO. The epidemiology and consequences of maternal malaria: a review of immunological basis. Acta tropica. 2003;87(2):193-205.
84. Dobaño C, Berthoud T, Manaca MN, Nhabomba A, Guinovart C, Aguilar R, Barbosa A, Groves P, Rodríguez MH, Jimenez A, Quimice LM. High production of pro-inflammatory cytokines by maternal blood mononuclear cells is associated with reduced maternal malaria but increased cord blood infection. Malaria Journal. 2018; 17:1-3.
85. Umbers AJ, Stanisic DI, Ome M, Wangnapi R, Hanieh S, Unger HW, Robinson LJ, Lufele E, Baiwog F, Siba PM, King CL. Does malaria affect placental development? Evidence from in vitro models. PLoS One. 2013;8(1):e55269.
86. Arama C, Quin JE, Kouriba B, Östlund Farrants AK, Troye-Blomberg M, Doumbo OK. Epigenetics and malaria susceptibility/protection: A missing piece of the puzzle. Frontiers in Immunology. 2018; 9:1733.

87. Gbedande K, Carpio VH, Stephens R. Using two phases of the CD 4 T cell response to blood-stage murine malaria to understand regulation of systemic immunity and placental pathology in Plasmodium falciparum infection. Immunological reviews. 2020;293(1):88-114.
88. Lindsay SW, Thomas MB, Kleinschmidt I. Threats to the effectiveness of insecticide-treated bednets for malaria control: thinking beyond insecticide resistance. The Lancet Global Health. 2021;9(9):e1325-1331.
89. Akinleye SO, Falade CO, Ajayi IO. Knowledge and utilization of intermittent preventive treatment for malaria among pregnant women attending antenatal clinics in primary health care centers in rural southwest, Nigeria: a cross-sectional study. BMC pregnancy and childbirth. 2009; 9:1-9.